SCHEMBL3656294

SCHEMBL3656294

COC(=O)C(C)(C)c1ccc(CCO)cc1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 7/20 0.54
CYP4F2 P78329 6/20 0.54
BRS3 P32247 1/20 0.54
PPARA Q07869 2/20 0.49
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
CA2 P00918 2/20 0.39
ESRRG P62508 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
KCNN4 O15554 1/20 0.38
CA1 P00915 1/20 0.38
ESRRB O95718 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24172240 0.90 CYP4A11 (0.57) CYP4A11CYP4F2BRS3PPARACNR1
SCHEMBL24171971 0.89 CYP4A11 (0.58) CYP4A11CYP4F2BRS3PPARACNR1
SCHEMBL28758271 0.86 BRS3 (0.54) CYP4A11CYP4F2BRS3CNR1CNR2
SCHEMBL5642443 0.86 BRS3 (0.50) CYP4A11CYP4F2BRS3PPARACNR1
SCHEMBL27796483 0.85 BRS3 (0.53) CYP4A11CYP4F2BRS3CNR1CNR2
SCHEMBL21629639 0.85 BRS3 (0.53) CYP4A11CYP4F2BRS3CNR1CNR2
SCHEMBL23583035 0.83 NR1H4 (0.54) BRS3PPARAALDH1A1
SCHEMBL8584934 0.83 PLK1 (0.53) BRS3ALDH1A1POLB
SCHEMBL992232 0.83 CYP4F2 (0.57) CYP4A11CYP4F2BRS3PPARACNR2
SCHEMBL8974321 0.83 CNR1 (0.54) BRS3CNR1CNR2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129039-A1 NOVEL PROCESS FOR THE PREPARATION OF BILASTINE AND INTERMEDIATES THEREOF BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) 2025-04-24 US disclosed
WO-2023037184-A2 NOVEL PROCESS FOR THE PREPARATION OF BILASTINE AND INTERMEDIATES THEREOF BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2023-03-16 WO disclosed
CN-110698343-B Synthesis method of bilastine intermediate 荆门医药工业技术研究院 2022-04-01 CN disclosed
CN-110698343-B Synthesis method of bilastine intermediate 荆门医药工业技术研究院 2022-04-01 CN disclosed
CN-113979960-B Preparation method of bilastine intermediate 南京桦冠生物技术有限公司 2022-03-18 CN disclosed
CN-113979960-A Preparation method of bilastine intermediate 南京桦冠生物技术有限公司 2022-01-28 CN disclosed
CN-107365297-B Preparation method and intermediate of 2-methyl-2' -phenylpropionic acid derivative 罗欣药业(上海)有限公司 2020-07-03 CN disclosed
CN-110698343-A Synthesis method of bilastine intermediate 荆门医药工业技术研究院 2020-01-17 CN disclosed
CN-110698343-A Synthesis method of bilastine intermediate 荆门医药工业技术研究院 2020-01-17 CN disclosed
CN-104402773-A Process for the preparation of 2-methyl-2' -phenylpropionic acid derivatives and intermediate compounds YUHAN CORP 2015-03-11 CN disclosed
US-20130116439-A1 PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS YUHAN CORPORATION (KR) 2013-05-09 US disclosed
US-7863452-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2011-01-04 US disclosed
EP-2240464-A2 PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS Yuhan Corporation (KR) 2010-10-20 EP disclosed
WO-2009102155-A2 PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS YUHAN CORPORATION (KR) 2009-08-20 WO disclosed
US-20090124810-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2009-05-14 US disclosed
US-7176318-B2 Processes for the production of fexofenadine TEXCONTOR ESTABLISSEMENT (LI) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124810-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES HADHB, CPT1B, PDHB CYP4A11 1616/4885CYP4F2 603/4885BRS3 1311/4885
US-20130116439-A1 PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS HRH2, HRH4, HNMT CYP4A11 232/4885CYP4F2 750/4885BRS3 1384/4885
US-20250129039-A1 NOVEL PROCESS FOR THE PREPARATION OF BILASTINE AND INTERMEDIATES THEREOF CYP4B1, CYP3A4, CYP7A1 CYP4A11 16/4885CYP4F2 64/4885BRS3 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.